These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 9499974)

  • 41. [Significance of cyclosporin A absorption for effective immunomodulatory therapy after high-risk keratoplasty].
    Bailly N; Dunewa I; Schlattmann P; Rieck PW
    Ophthalmologe; 2008 May; 105(5):457-62. PubMed ID: 18299847
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Penetrating keratoplasty in patients with atopic dermatitis with and without systemic cyclosporin A.
    Reinhard T; Möller M; Sundmacher R
    Cornea; 1999 Nov; 18(6):645-51. PubMed ID: 10571292
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty.
    Inoue K; Amano S; Kimura C; Sato T; Fujita N; Kagaya F; Kaji Y; Oshika T; Tsuru T; Araie M
    Jpn J Ophthalmol; 2000; 44(3):302-5. PubMed ID: 10913651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systemic ciclosporin A in high-risk keratoplasties.
    Reinhard T; Sundmacher R; Heering P
    Graefes Arch Clin Exp Ophthalmol; 1996 Aug; 234 Suppl 1():S115-21. PubMed ID: 8871161
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Immune suppression by combination therapy with basiliximab and cyclosporin in high risk keratoplasty. A pilot study].
    Schmitz K; Hitzer S; Behrens-Baumann W
    Ophthalmologe; 2002 Jan; 99(1):38-45. PubMed ID: 11840795
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Preventive systemic cyclosporin A in risk keratoplasty].
    Rossa V; Sundmacher R; Heering P
    Klin Monbl Augenheilkd; 1990 Dec; 197(6):466-9. PubMed ID: 2087048
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term outcome of systemic cyclosporine treatment following penetrating keratoplasty.
    Inoue K; Kimura C; Amano S; Sato T; Fujita N; Kagaya F; Kaji Y; Tsuru T; Araie M
    Jpn J Ophthalmol; 2001; 45(4):378-82. PubMed ID: 11485770
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Systematic review of penetrating keratoplasty rejection treated by immunosuppressants].
    Sun YJ; Li AP; Pan ZQ; Luo F; Zou LH
    Zhonghua Yan Ke Za Zhi; 2010 Dec; 46(12):1122-7. PubMed ID: 21211228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of cyclosporin in the treatment of steroid resistant post-keratoplasty atopic sclerokeratitis.
    Daniell MD; Dart JK; Lightman S
    Br J Ophthalmol; 2001 Jan; 85(1):91-2. PubMed ID: 11133720
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Topical cyclosporin: a treatment for corneal graft rejection.
    Ross AH; Cook SD
    Clin Exp Ophthalmol; 2008 Jul; 36(5):399-400. PubMed ID: 18925911
    [No Abstract]   [Full Text] [Related]  

  • 51. Topical cyclosporin A in the treatment of corneal graft reaction.
    Hoffmann F; Wiederholt M
    Cornea; 1986; 5(3):129. PubMed ID: 2980826
    [No Abstract]   [Full Text] [Related]  

  • 52. [Immune suppression following perforating keratoplasty].
    Birnbaum F; Reis A; Reinhard T
    Ophthalmologe; 2007 May; 104(5):371-2. PubMed ID: 17380336
    [No Abstract]   [Full Text] [Related]  

  • 53. [Immunosuppressive agents and keratoplasties. Apropos of 5 cases].
    Lagoutte F; Pommeraud D; Le Rebeller MJ
    Bull Soc Ophtalmol Fr; 1977; 77(7-8):709-12. PubMed ID: 350446
    [No Abstract]   [Full Text] [Related]  

  • 54. The high-risk keratoplasty patient--quo vadis?
    Bouchard CS; Cavanagh HD
    Cornea; 1994 Jan; 13(1):1-3. PubMed ID: 8131400
    [No Abstract]   [Full Text] [Related]  

  • 55. [Comparative study of penetrating 8 and 9 mm diameter keratoplasties].
    Pouliquen Y; Petroutsos G; Guillot N; Giraud JP
    Bull Soc Ophtalmol Fr; 1982 Mar; 82(3):341-3. PubMed ID: 6749314
    [No Abstract]   [Full Text] [Related]  

  • 56. [Immune reaction after penetrating keratoplasty. II. Prevention and therapy].
    Pleyer U; Rieck P; Ritter T; Hartmann C
    Ophthalmologe; 1998 Jun; 95(6):444-59. PubMed ID: 9703727
    [No Abstract]   [Full Text] [Related]  

  • 57. Topical tacrolimus for high-risk corneal transplantation: a randomized, clinical trial.
    Shimazaki J; Tomida D; Yagi-Yaguchi Y; Satake Y; Yamaguchi T
    BMC Ophthalmol; 2024 Jun; 24(1):251. PubMed ID: 38867175
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systemic cyclosporine and corneal transplantation.
    Ziaei M; Ziaei F; Manzouri B
    Int Ophthalmol; 2016 Feb; 36(1):139-146. PubMed ID: 26463642
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systemic cyclosporin A in high risk penetrating keratoplasties: a case-control study.
    Poon AC; Forbes JE; Dart JK; Subramaniam S; Bunce C; Madison P; Ficker LA; Tuft SJ; Gartry DS; Buckley RJ
    Br J Ophthalmol; 2001 Dec; 85(12):1464-9. PubMed ID: 11734522
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Treatment with cyclosporin A, with low doses, in high-risk penetrating keratoplasties. A bi-centric study of 90 cases].
    Robert PY; Delbosc B; Preux PM; Monnot PH; Drouet M; Peyronnet P; Adenis JP
    J Fr Ophtalmol; 1997; 20(7):507-14. PubMed ID: 9499974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.